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Mucins are highly glycosylated proteins that are expressed in
cancers of epithelial origin in an underglycosylated form. MUC1
is such a mucin and is the most abundant mucin in breast cancers
(Ceriani et al, 1983; Sekine et al, 1985; Gum et al, 1989, 1990; Lan
et al, 1990; McKenzie and Xing 1990; Strauss et al, 1992). In
normal tissues, but not cancers, MUC1 is highly glycosylated and
its expression is largely restricted to the apical surface of luminal
cells, two factors which combine to make MUC1 in normal tissues
inaccessible to the immune system. Thus the underglycosylated
MUC1 protein on cancer cells is a potential target for vaccine
therapy (Girling et al, 1989; Hilkens et al, 1989; Sell, 1990;
Devine et al, 1991; Itzkowitz et al, 1991; Jerome et al, 1991).
MUC1 mucin is a high molecular weight molecule with
multiple tandem repeats of peptide (VTSAPDTRPAPGSTAP-
PAHG). The most immunogenic position is APDTRPA which
includes the epitope recognized by a variety of monoclonal anti-
bodies (mAbs) (Xing et al, 1992), normal sera (von Mensdorff-
Pouilly et al, 1996), and cytotoxic T-cells (Nieves et al, 1995).
Zhang et al (1996) were able to vaccinate mice with MUC1
peptide containing 1.5 tandem repeats conjugated to keyhole
limpet haemocyanin (KLH) and mixed with QS-21, and were able
to induce high titre antibody (but no evidence of T-cell immunity)
against MUC1 and tumour cells expressing MUC1. Moreover,
these vaccinations were able to confer protection in these mice
when they were challenged with MUC1-expressing tumour cells.
Consequently, patients with AJCC stage I–III breast cancer and
rising CA15.3 or CEA markers, and patients with AJCC stage IV
breast cancer who were currently free of disease, were vaccinated
with a MUC1-KLH plus QS-21 vaccine (Gilewski et al, 1998).
The vaccine induced high titres of IgM and IgG antibodies against
the MUC1 peptide. However, the IgM antibodies from only four of
the six patients reacted moderately with tumour cells expressing
the MUC1 antigen and IgG antibodies from only three of six
patients reacted (weakly) with tumour cells. The goal of the study
described here was to determine the precise specificity of these
MUC1 immune sera in hopes that it would lead us to an explana-
tion for why these high titer MUC1 antisera showed relatively
weak reactivity against MUC1 on tumour cells.
MATERIAL AND METHODS
Materials
MUC1 was synthesized using an Applied Biosystems Model 431A
automated peptide synthesizer by the MSKCC microchemistry
core facility. The amino acid (aa) sequence is (c)VTSAPDTR-
PAPGSTAPPAHGVTSAPDTRPA. This represents 1.5 repeats of
the 20 aa MUC1 peptide, with the repeated section representing
the most immunogenic epitope. Cysteine was added to the N-
terminal carboxyl end to facilitate attachment to a carrier protein.
Peptides used for inhibition assays were made by Research
Genetics (Huntsville, AL, USA). KLH used as a carrier protein
was purchased from PerImmune Inc. (Rockville, MD, USA). QS-
21 adjuvant, a purified saponin fraction, was obtained from Aquila
Biopharmaceuticals Inc. (Farmingham, MA, USA). Monoclonal
antibody HMFG-2 against MUC1 was kindly provided by Dr
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Summary The mucin MUC1 is expressed on breast cancers in an underglycosylated form compared to normal tissues and is therefore a
potential target for cancer immunotherapy. MUC1 contains multiple tandem repeats of the 20 amino acid (aa) peptide
(VTSAPDTRPAPGSTAPPAHG). The APDTRPA epitope is particularly immunogenic since it is recognized by a variety of murine monoclonal
antibodies and by some sera and cytotoxic T-cells from unimmunized patients with epithelial cancers. We have prepared a 30 aa peptide
(C)VTSAPDTRPAPGSTAPPAHGVTSAPDTRPA with cysteine at the N-terminal end, and used the cysteine for chemical conjugation to
keyhole limpet haemocyanin (KLH). Six breast cancer patients immunized with this conjugate plus the immunological adjuvant QS-21 have
all produced high titre (by ELISA) IgG and IgM antibodies against the 30 aa MUC1 peptide, but these sera reacted moderately, or not at all,
with MUC1-positive tumour cells. To understand this specificity better, we prepared a series of smaller peptides to determine the epitopes
recognized by these immune sera in inhibition assays. Only peptides containing APDTRPA at the C-terminal end were able to completely
inhibit ELISA reactivity for the full 30 aa peptide. No sera were completely inhibited by APDTR, APDTRP, PDTRPA or any other peptides that
did not contain the full APDTRPA epitope. Remarkably, sera from all six patients recognized this same epitope and were completely inhibited
by only this epitope. The specificity of these sera (1) primarily for C-terminal APDTRPA, and the absence of this epitope at the C-terminal end
of any tumour mucins, and (2) the N-terminal APDTRPA alanine, which is normally buried in the b turn MUC1 assumes in its secondary
structure may explain the moderate to weak reactivity of these high titer sera against MUC1-positive tumour cells.
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Joyce Taylor-Papadimitrou (Taylor-Papadimitrou et al, 1981), and
the human breast tumour cell line MCF-7 (Soule et al, 1973) was
obtained from Dr Neil Rosen (Memorial Sloan-Kettering Cancer
Center).
Conjugation of MUC1 peptide to KLH
Covalent attachment to KLH was achieved with m-malemido-
benzoyl-N-hydroxysuccinimide ester (Pierce Co., Rockford, IL,
USA) which couples the terminal cysteine on the MUC1 peptide
to amino groups on KLH. The MBS–dimethylformamide is mixed
with KLH and the unconjugated MBS eliminated by passage over
a G25 sephadex column. The malemide-activated KLH was then
added to the MUC1 peptide and, following a 3-h incubation, the
free peptide was eliminated using a 30 000 MW centriprep filter as
previously described (Amicon Inc., Beverly, MA, USA) (Zhang
et al, 1996). The resultant conjugant was washed and tested for
sterility, purity and safety. The ratio of MUC1 peptide molecules
per KLH molecule was 540 to 1.
Patients and treatment schedule
Sera from the initial six patients in a larger MUC1 vaccination trial
were studied. Patients with AJCC stage I–III breast cancer and
rising CA15.3 or CEA markers, and patients with AJCC stage IV
breast cancer who were currently free of disease, were vaccinated.
Accrual of patients was done under an IRB-approved protocol.
MUC1-KLH conjugate containing 100 mg of MUC1 plus 100 mg
QS-21 was administered subcutaneously at weekly intervals for
three doses, followed by a 4-week break and then a fourth vaccina-
tion. This was followed by a 3-month break and a fifth vaccination.
Enzyme-linked immunosorbent assay (ELISA)
ELISAs were performed using alkaline–phosphatase conjugated
goat anti-(human) IgM (Kierkegaard and Perry Labs,
Gaithersburg, MD, USA) as previously described (Zhang et al,
1996). To detect IgG against MUC1, an unlabelled mouse anti-
human IgG (Southern Biotech, Birmingham, AL, USA) was used
followed by alkaline–phosphatase labelled goat anti-mouse IgG
(Southern Biotech). A total of 0.2 mg of MUC1 peptide was plated
using carbonate buffer (pH 10) into Nunc (Nunc, Denmark)
96-well plates. Absorbance was measured at 414 nm and the
highest serum dilution with an absorbance of at least 0.100 was
defined as the antibody titre. Plates were incubated before
measuring absorbance, at 37°C for approximately 20 min.
Inhibition ELISAs were performed to determine more sensitively
the specificity of the antibodies. For these assays, the designated
amount of peptide was incubated with patient sera for 1 h and the
mixture then tested on the 30 aa MUC1 peptide by ELISA.
Percentage inhibition was calculated on the basis of the difference
in absorbance from the uninhibited serum.
% inhibition = absorbance of uninhibited serum – 
absorbance of inhibited serum/
absorbance of uninhibited serum
In Figures 1 and 2, error bars have been calculated and added to
account for variability between experiments and reproducibility of
the data. For each peptide at each of the concentrations, the mean
value of percent inhibition within four different repeats of experi-
ments was calculated and then error bars were calculated to reflect
the variability of the mean at that concentration, as previously
described (Woolson, 1987).
Flow cytometry
Tumour cells (1 ´ 107) were incubated with 20 ml of 1:10 diluted
sera or 1:2 diluted mAb supernatant on ice for 30 min. After
washing with 3% fetal calf serum (FCS), the cells were incubated
with 20 ml of 1:25 diluted fluorescence in situ hybridization
(FITC)-labelled goat anti-human IgM or IgG (Southern Biotech.
Assoc. Inc., Birmingham, AL, USA). The positive population
of cells was quantitated by flow cytometry (Becton Dickinson
FACSCAN, Sanjose, CA, USA). Pre-vaccination sera was used to
set the gate at 10% background for each post-vaccination sample.
RESULTS
Direct tests
Antibody titres against MUC1 were measured by ELISA. High
titre IgM and IgG antibodies against MUC1 peptide were induced
in all patients. Pre-vaccination serum titres were low in all
patients, except patient 6 who had a pretreatment IgM titre of
Table 1 Serological results of six breast cancer patients vaccinated with MUC1 (30 aa)-KLH conjugate plus QS-21
Patient Peak ELISA titre
FACS analysis on MCF-7 cell line against MUC1 (30 aa)
IgM IgG IgM IgG
Pre-vaccination Post-vaccination Pre-vaccination Post-vaccination
Positive Mean Positive Mean Positive Mean Positive Mean
cells (%) fluorescence cells (%) fluorescence cells (%) fluoresence cells (%) fluorescence
intensity intensity intensity intensity
1 2560 2560 9.79 11.14 64.71 33.28 10.63 9.43 38.11 16.86
2 1280 2560 10.92 31.23 25.5 49.98 10.4 4.92 24.28 7.85
3 20 480 2560 10.58 12.84 84.28 66.41 9.7 9.93 34.06 17.20
4 2560 2560 9.72 28.51 2.49 17.49 10.93 7.24 18.41 10.36
5 2560 10 240 9.95 10.03 91.36 45.2 10.80 4.47 16.57 5.62
6 20 480 10 240 9.38 15.38 59.67 41.77 11.21 4.56 21.34 5.811808 S Adluri et al
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1:160 (see Table 1). MCF-7 cells, which express MUC1 antigen,
were also used as targets in FACS analysis (Table 1) to determine
whether the induced anti-MUC1 antibodies were reactive with the
cell surface. Patients 1, 3, 5 and 6 showed moderately increased
IgM reactivity after immunization. Weak anti-MUC1 IgG reac-
tivity against MCF-7 cells was induced in patients 1, 2 and 3.
HMFG-2, the positive control MUC1 mAb, reacted strongly with
75% of MCF-7 cells.
Inhibition tests
Sera from immunized patients were incubated (inhibited) with
various amounts of small MUC1 peptides. The ELISA results
obtained with sera (inhibited or not) from patient 2 are shown in
Figures 1 and 2. Complete inhibition of all IgM and IgG reactivity
was achieved with the APDTRPA peptide, or longer peptides
containing the full APDTRPA epitope at the C-terminal position.
Partial inhibition of IgM reactivity was seen with the peptide
containing APDTRPA in mid peptide. No inhibition was seen
when the full APDTRPA was not present. Tables 2 and 3 summa-
rize the IgM and IgG inhibition results for all six patients. Table 2
shows that the specificity of induced anti-MUC1 IgM antibodies
was almost exclusively for a terminal APDTRPA epitope in all six
patients. Only serum of patient 1 showed slight inhibition of IgM
reactivity with peptide when the APDTRPA epitope was in mid
peptide.
Table 3 shows the specificity of the induced anti-MUC1 IgG
antibodies. Here again strong inhibition was seen with the 30 aa
MUC1 peptide and other peptides with a terminal APDTRPA
epitope, in all six patients. However, some inhibition was also seen
when the APDTRPA was present in the middle of the peptide. In
addition, sera of patients 5 and 6 showed 1+ inhibition with a
peptide consisting of only the APDTR epitope, and sera of patients
4, 5 and 6 showed 1+ inhibition with a peptide that had no
APDTRPA sequence. Monoclonal antibody HMFG-2 was inhib-
ited with peptides that have APDTRPA epitope regardless of its
location. In addition, complete inhibition of HMFG-2 reactivity
was also possible with PDTRPAPGSTAPPAH, unlike any of the
immune sera, which all required the full APDTRPA epitope for
complete inhibition.
DISCUSSION
The structure of the MUC1 core protein consists of an N-terminal
protein sequence, followed by a variable number of tandem
repeats (VNTR) of the 20 aa peptide and, finally, the transmem-
Table 2 Inhibition of anti-MUC1 IgM reactivity in patient sera with MUC1 (30 aa) and other synthetic peptides
Patients
Positive
control
Peptide 1 2 3 4 5 6 HMFG-2
30 aa (1.5 repeats) 4+ 3+ 4+ 4+ 3+ 4+ 4+
PAHGVTSAPDTRPA 4+ 4+ 3+ 4+ 4+ 3+ 3+
APDTRPA 4+ 3+ 3+ 4+ 4+ 3+ 3+
VTSAPDTRPAPGS 1+ 0 0 0 0 0 4+
PDTRPAPGSTAPPAH 0 0 0 0 0 0 4+
PAPGSTAPPAHGVTS 0 0 0 0 0 0 0
PAHGVTS 0 0 0 0 0 0 0
TSAPDTR 0 0 0 0 0 0 0
APDTR 0 0 0 0 0 0 0
Grading scale: percent inhibition of 85–90% was given a grade of 4+, 70–85% was a 3+, 40–70% was 2+, 20–40% was 1+, below 20% was 0.
Table 3 Inhibition of anti-MUC1 IgG reactivity in patient sera with MUC1 (30 aa) and other synthetic peptides
Patients
Positive
control
Peptide 1 2 3 4 5 6 HMFG-2
30 aa (1.5 repeats) 4+ 4+ 4+ 4+ 4+ 4+ 4+
PAHGVTSAPDTRPA 4+ 4+ 3+ 4+ 4+ 4+ 2+
APDTRPA 3+ 3+ 3+ 4+ 4+ 4+ 4+
VTSAPDTRPAPGS 2+ 1+ 1+ 2+ 2+ 2+ 4+
PDTRPAPGSTAPPAH 0 0 0 1+ 1+ 0 4+
PAPGSTAPPAHGVTS 0 0 0 1+ 1+ 1+ 0
PAHGVTS 0 0 0 0 0 0 0
TSAPDTR 0 0 0 0 1+ 1+ 0
APDTR 0 0 0 0 1+ 1+ 0
Grading scale: percent inhibition of 85–90% was given a 4+ grade, 70–85% was 3+, 40–70% was 2+, 20–40% was 1+, below 20% was 0.Specificity of anti-MUC1 antibodies 1809
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Figure 1 Inhibition of anti-MUC1 IgM reactivity in post-immunization serum of patient 2. The inhibitory peptides were VTSAPDTRPAPGS,
PDTRPAPGSTAPPAH, PAPGSTAPPAHGVTS, PAHGVTSAPDTRPA, PAHGVTS, APDTRPA, APDTR, TSAPDTR and MUC1 (30 aa). Peptides were used at
various concentrations to inhibit anti-MUC1 IgM reactivity and then tested by ELISA to measure percent inhibition. MUC1 peptide was coated in each well at 0.2
mg per well. The serum was used at a dilution of 1:801810 S Adluri et al
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Figure 2 Inhibition of anti-MUC1 IgG reactivity in post-immunization serum of patient 2. The inhibitory peptides were VTSAPDTRPAPGS,
PDTRPAPGSTAPPAH, PAPGSTAPPAHGVTS, PAHGVTSAPDTRPA, PAHGVTS, APDTRPA, APDTR, TSAPDTR and MUC1 (30 aa). Peptides were used at
various concentrations to inhibit anti-MUC1 IgG reactivity and then tested by ELISA to measure percent inhibition. MUC1 peptide was coated in each well at 0.2
mg per well. The serum was used at a dilution of 1:320Specificity of anti-MUC1 antibodies 1811
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brane region and cytoplasmic tail (Price et al, 1990). The VNTR
region seems to be the most immunogenic region with the
APDTRPA sequence being especially immunogenic. We have
synthesized a synthetic peptide 30 amino acids long that contains
1.5 tandem repeats. This MUC1 peptide has two APDTRPA
sequences: one toward the –NH2-terminal (but not at the terminal
end) and the other at the –COOH-terminal. KLH is conjugated to
the –NH2-terminal. Inhibition results with high titre immune sera
drawn from breast cancer patients after vaccination indicated that
the anti-MUC1 IgM antibodies generated against this vaccine
were inhibited specifically and exclusively with peptides that have
the full APDTRPA epitope present terminally. The IgG anti-
MUC1 antibodies also reacted preferentially with the terminal
APDTRPA epitope, but weak reactivity was also seen when the
APDTRPA epitope was present in the middle of the peptide and
with other portions of the MUC1 peptide.
The antibodies induced in breast cancer patients against this
synthetic MUC1 fail to react strongly with mucin on tumour cells.
Comparing the reactivity of monoclonal antibody HMFG-2 to
these MUC1 anti-sera, HMFG-2 was inhibited by PDTRPA
peptide regardless of whether it was expressed terminally or in the
middle of the peptide, and HMFG-2 reacted strongly with tumour
mucins. Studies of the secondary structure of the protein mucin
core of MUC1, suggest that the protein undergoes a b turn which
results in the PDTRPAP epitope expressed at the surface of the
mucin molecule where it is accessible to antibodies while much of
the rest of the VNTR repeat lies buried within the helix (Price,
1988; Price et al, 1990; Price and Tendler, 1993).
The goal of our MUC1 vaccination programme was to induce
antibodies that react well with both the synthetic immunogen and
tumour cells, like mAb HMFG-2. Based on the results presented
here, hypotheses for the relatively modest reactivity of our
immune sera with tumour MUC1 are first that the N-terminal
alanine, in APDTRPA is not accessible in natural mucins. This
alanine is necessary for recognition by our immune sera, but not
by HMFG-2. Second, in addition to making the N-terminal alanine
of APDTRPA inaccessible, the secondary structure with its b turns
assumed by natural MUC1 may have other consequences in terms
of the way the individual amino acids in APDTRPA are exposed or
the way multiple APDTRPA epitopes in close proximity are recog-
nized by the immune system. Third, the sequence RPA must be at
the C-terminal end for strong recognition by our sera, but this is
not necessary for HMFG-2 and never occurs in tumour MUC1
(Price et al, 1990). The MUC1 vaccine tested here contained two
APDTRPA epitopes, but the APDTRPA at the –COOH-terminal
may have been the only one exposed to the immune system, since
the other APDTRPA epitope was adjacent to the conjugation site
and may have been obstructed due to its proximity to KLH.
We have addressed these three hypotheses with two responses.
First, by constructing a 32 aa MUC1 peptide containing two copies
of the APDTRPA repeat, neither of which is at the C-terminal end,
to force the immune system to recognize the APDTRPA epitope in
the middle of the peptide as it occurs naturally. Second, by
constructing a 106 aa MUC1 peptide which should naturally
assume a b helix configuration similar to the proposed configura-
tion on tumour cells. This should force the immune system to focus
on multiple copies of the 20 aa repeat, to see PDTRPA and other
potential epitopes in a more natural configuration. In both cases the
peptides will be linked to KLH and mixed with QS-21 and the
vaccines administered to breast cancer patients in the adjuvant
setting. Supporting this approach, Karanikas et al (1997), have
vaccinated patients with a 106 aa MUC1 peptide conjugated to
mannan (polymanose). They have reported that most of the anti-
bodies in these studies recognized non-APDTRPA epitopes such as
STAPPAHG and PAPGSTAP (Karanikas et al, 1997). It therefore
seems possible that vaccination with a longer peptide might result
in recognition of additional epitopes.
A fourth hypothesis, that the peptide should be partially or
completely glycosylated before the proper secondary structure is
assumed, will be more difficult to address. There are differing
points of view on the proper carbohydrate epitopes and glycosyla-
tion sites (Stadie et al, 1995; Karsten et al, 1998), preparation of
sufficient glyosylated MUC1 for clinical trials is difficult, and the
murine response to vaccination with the same MUC1-KLH
vaccine described in this study was high titre IgM and IgG anti-
bodies that reacted strongly with MCF-7, so experiments in the
mouse will not be helpful (Zhang et al, 1996). In addition,
Apostolopoulos et al (1998) have suggested that presence of anti-
gal antibodies, which are present in humans, but not the mouse,
affects the immune response against MUC1. Consequently, only
trials in humans can identify the correct hypothesis and the appro-
priate vaccine.
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